An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen.
about
Immunogenicity of protein therapeutics: The key causes, consequences and challengesT cells that are naturally tolerant to cartilage-derived type II collagen are involved in the development of collagen-induced arthritisThe genetics of rheumatoid arthritis and the need for animal models to find and understand the underlying genesRheumatoid arthritis viewed using a headache paradigm.Association of MHC and rheumatoid arthritis. HLA-DR4 and rheumatoid arthritis: studies in mice and menA systematic bioinformatics approach for selection of epitope-based vaccine targetsStructure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritisCrystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic proteinEnhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE)Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritisSmall organic compounds enhance antigen loading of class II major histocompatibility complex proteins by targeting the polymorphic P1 pocket.Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC moleculesOn the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.The value of animal models in predicting genetic susceptibility to complex diseases such as rheumatoid arthritisIdentification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice.Transgenic mouse models of rheumatoid arthritis.HLA class II transgenic mice: models of the human CD4+ T-cell immune response.Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesThe rheumatoid arthritis HLA-DRB1 shared epitope.Host differences in influenza-specific CD4 T cell and B cell responses are modulated by viral strain and route of immunization.A role for calreticulin in the pathogenesis of rheumatoid arthritis.Transgenic models of autoimmune disease.Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources.A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes.HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation.MHC molecules in health and disease: At the cusp of a paradigm shift.New insights into the functional role of the rheumatoid arthritis shared epitope.The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.Collagen type II and a thermo-responsive polymer of N-isopropylacrylamide induce arthritis independent of Toll-like receptors: a strong influence by major histocompatibility complex class II and Ncf1 genes.Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice.Mice lacking all conventional MHC class II genes.Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory DiseasesHumanized animal models for autoimmune diseases.Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis.Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models.Anergy in peripheral memory CD4(+) T cells induced by low avidity engagement of T cell receptor.MHC class II proteins and disease: a structural perspective.Crystal structures of T cell receptor (beta) chains related to rheumatoid arthritis.Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice.
P2860
Q24633296-F0D07506-26CF-474E-AB4A-6BC5BB956DB7Q24792514-83ABF09B-406E-443A-87BF-878EF1965954Q24805318-1AEB3A18-3567-4B47-B747-9276CDADAA62Q24806869-507EDA15-7CC0-44D8-B720-C37450CD6E30Q24807019-DF1AB02E-878B-4EBE-8995-67372BBEB835Q27481378-EBD26C0B-0193-44F3-AC0D-1C191C233A2DQ27653688-49D4AAAD-3AF3-49D0-9E31-CE6AE0C524FFQ27765717-AD344D6A-692B-408E-B5A6-ED1B9D4CBEE9Q28476101-0ABA9120-C24E-45D4-ADD5-7FAD5C03D6F7Q31089923-97161BCF-2DAF-41C1-A483-CF023E9632D8Q33258637-0E36C4A4-7FC6-4F08-BE89-95C25015C0A8Q33324394-9D716CBB-0B0C-4DAD-9683-959BEC9859B3Q33333935-B1813607-DB7E-47D5-AEB3-D22F2D568C5CQ33458893-30829540-75AB-4574-98B2-4BA4F6CCE139Q33554688-36B8922A-7505-407F-A74E-5DFDA974D18FQ33713326-D6A52D8D-BB22-4BFD-9D79-DC66415F2530Q33815475-3FE0A068-9C4F-4EA9-A783-0C665C9259FEQ33895804-10A81819-607F-4D72-8E52-3E43D94CF6A2Q34067135-8B80DC89-D042-4799-B2F5-21DA957FC7F4Q34212258-53E1AD6B-8FFE-42F9-9334-0559E5E9AF33Q34222660-CE79614F-960B-4E16-85E4-991AA7136B52Q34554029-AD1CB224-9AAC-4F50-9107-26535A145404Q34561569-99D72999-B7B2-4FAB-973B-6F106F3A7112Q34679722-51E79E32-567C-4CD0-95A3-87101CB05338Q34948997-7B0499BB-3D55-45F7-B5DD-15190DC16B89Q35107011-678E725D-E51E-4687-8E1C-86543E115F76Q35156717-ABFBA46C-CC79-427C-9353-DC005105BE8DQ35165161-A6767C3F-62ED-4E81-AEED-9AA844CD8BCFQ35475327-818E77A6-7320-4E47-9DCB-1F7090796950Q35605653-EC72CF9E-E43D-4ED4-9788-742347FEF9FCQ35620743-304178DB-880C-4B96-9EC5-F0FE4C2D876BQ35738486-AB3F42BC-17EA-4A66-9518-B1C6AF447F34Q35754332-D1235FB0-3958-480D-A4ED-F5CF3EB2F305Q35823339-24CF31F6-E1F1-4C70-B8ED-5E4A3623FB57Q36278295-95749221-2EF6-47E5-8E70-86779A330380Q36288434-EAC42DFF-6764-44D3-BEC0-0153E6FFF262Q36376336-06CCE50D-C9E3-465A-A1F2-A341D36EEEF3Q36430136-137E9775-65F1-49B3-85F9-D15F4502839BQ36476612-B20E4E87-1DC9-4243-A55F-B1DEB89D7C27Q36498837-CC7CC722-E97B-468C-8C47-AEF7879CD699
P2860
An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
An HLA-DR1 transgene confers s ...... d with human type II collagen.
@ast
An HLA-DR1 transgene confers s ...... d with human type II collagen.
@en
type
label
An HLA-DR1 transgene confers s ...... d with human type II collagen.
@ast
An HLA-DR1 transgene confers s ...... d with human type II collagen.
@en
prefLabel
An HLA-DR1 transgene confers s ...... d with human type II collagen.
@ast
An HLA-DR1 transgene confers s ...... d with human type II collagen.
@en
P2093
P2860
P356
P1476
An HLA-DR1 transgene confers s ...... ed with human type II collagen
@en
P2093
D M Zaller
E F Rosloniec
J M Stuart
K B Whittington
M Gumanovskaya
P2860
P304
P356
10.1084/JEM.185.6.1113
P407
P577
1997-03-01T00:00:00Z